Trademarks = 4

Forward Citations = 0

Loading Chart...

8 inventors (with patents filed for the assignee):

Xiaojun Liu (4 out of 5 patents)

Yangbing Zhao (4 out of 4 patents)

Wei Pan (1 out of 4 patents)

4. Jie Wang (1 out of 14 patents)

5. Jintao Feng (1 out of 1 patent)

6. Xiaodong Song (1 out of 1 patent)

7. Bin Li (1 out of 41 patents)

8. Gengzhen Zhu (1 out of 1 patent)

4 patents: Sort by Forward Citations

1. 11993659 - BCMA targetting antibodies, chimeric antigen receptors, and uses thereof (2024-05-28),

2. 11897966 - Mesothelin-targetting antibodies, chimeric antigen receptors, and uses thereof (2024-02-13),

3. 11767368 - Antigen-binding protein and use thereof (2023-09-26),

4. 11667723 - Lymphocytes-antigen presenting cells co-stimulators and uses thereof (2023-06-06),

UTC Therapeutics (Shanghai) Co., Ltd. is a biopharmaceutical company dedicated to developing innovative cell therapies for cancer treatment. Founded in 2016, the company focuses on research and development of novel cellular immunotherapies to address unmet medical needs. UTC Therapeutics is committed to improving patient outcomes through cutting-edge cell therapy solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

4 Patents

#470 in Shanghai

#5,549 in China

Shanghai, China

Utc Therapeutics (shanghai) Co., Ltd.